Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedApr 02, 2026
DataAggregated Company Financials
Companies147
  • 7D6.3%
  • 3M-2.0%
  • 1Y1.2%
  • YTD-0.5%

Over the last 7 days, the Healthcare industry has risen 5.0%, driven by gains from Swedish Orphan Biovitrum of 7.2%. In the same time, Diamyd Medical was down 90%. In the past year, the industry is down 3.2%. Earnings are forecast to grow by 24% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 02 Apr 2026SEK 580.7bSEK 228.9b-SEK 2,929,720,236.8631.8x-198.2x2.5x
Sat, 28 Feb 2026SEK 577.0bSEK 229.0b-SEK 2,353,168,385.7233.4x-245.2x2.5x
Mon, 26 Jan 2026SEK 601.1bSEK 257.5bSEK 4.9b40x123.9x2.3x
Wed, 24 Dec 2025SEK 583.9bSEK 230.5bSEK 3.6b43.6x160x2.5x
Fri, 21 Nov 2025SEK 583.7bSEK 230.8bSEK 3.2b44x181.4x2.5x
Sun, 19 Oct 2025SEK 601.1bSEK 227.1bSEK 6.7b42.6x90x2.6x
Tue, 16 Sep 2025SEK 607.3bSEK 227.0bSEK 6.6b45x92.1x2.7x
Thu, 14 Aug 2025SEK 611.0bSEK 226.8bSEK 6.6b46.8x92.6x2.7x
Sat, 12 Jul 2025SEK 642.1bSEK 226.7bSEK 6.0b44.9x106.7x2.8x
Mon, 09 Jun 2025SEK 630.5bSEK 226.5bSEK 5.8b43.8x107.9x2.8x
Wed, 07 May 2025SEK 595.0bSEK 223.5bSEK 4.9b37x121.1x2.7x
Fri, 04 Apr 2025SEK 556.3bSEK 221.0bSEK 5.4b34.1x103x2.5x
Sun, 02 Mar 2025SEK 587.0bSEK 206.2bSEK 4.2b36.1x140.1x2.8x
Tue, 28 Jan 2025SEK 583.0bSEK 202.7b-SEK 2,675,919,582.6740.6x-217.9x2.9x
Thu, 26 Dec 2024SEK 577.8bSEK 202.8b-SEK 2,503,902,169.1638.4x-230.7x2.8x
Sat, 23 Nov 2024SEK 506.5bSEK 199.8b-SEK 2,658,058,690.1536.2x-190.6x2.5x
Mon, 21 Oct 2024SEK 599.2bSEK 198.9b-SEK 3,204,651,387.2939.4x-187x3x
Wed, 18 Sep 2024SEK 621.5bSEK 200.0b-SEK 2,795,397,479.0041.3x-222.3x3.1x
Fri, 16 Aug 2024SEK 594.5bSEK 200.0b-SEK 2,551,077,034.8441.1x-233x3x
Sun, 14 Jul 2024SEK 585.4bSEK 196.2b-SEK 3,104,678,694.3238.3x-188.5x3x
Tue, 11 Jun 2024SEK 564.1bSEK 195.7b-SEK 3,147,496,847.3936x-179.2x2.9x
Thu, 09 May 2024SEK 545.0bSEK 196.8b-SEK 2,719,308,488.9535.9x-200.4x2.8x
Sat, 06 Apr 2024SEK 521.8bSEK 192.8b-SEK 3,320,827,050.4345.6x-157.1x2.7x
Mon, 04 Mar 2024SEK 512.0bSEK 192.0b-SEK 3,663,022,021.3645.1x-139.8x2.7x
Wed, 31 Jan 2024SEK 695.1bSEK 191.8b-SEK 796,231,363.0049.1x-873x3.6x
Fri, 29 Dec 2023SEK 542.4bSEK 191.0b-SEK 960,823,433.0047.2x-564.5x2.8x
Sun, 26 Nov 2023SEK 501.3bSEK 190.1b-SEK 1,200,469,045.0050.2x-417.6x2.6x
Tue, 24 Oct 2023SEK 424.7bSEK 186.4b-SEK 1,832,666,692.0032.4x-231.7x2.3x
Thu, 21 Sep 2023SEK 461.5bSEK 185.6b-SEK 2,027,819,006.0035.4x-227.6x2.5x
Sat, 19 Aug 2023SEK 457.5bSEK 185.0b-SEK 1,068,478,910.0037.5x-428.1x2.5x
Mon, 17 Jul 2023SEK 465.5bSEK 179.8b-SEK 1,518,021,230.0044.4x-306.7x2.6x
Wed, 14 Jun 2023SEK 520.2bSEK 178.8b-SEK 763,490,619.0045.9x-681.3x2.9x
Fri, 12 May 2023SEK 521.9bSEK 177.0b-SEK 880,521,138.0042.4x-592.8x2.9x
Sun, 09 Apr 2023SEK 504.0bSEK 172.7b-SEK 1,416,903,805.0035.7x-355.7x2.9x
Price to Earnings Ratio

-355.7x


Total Market Cap: SEK 504.0bTotal Earnings: -SEK 1,416,903,805.00Total Revenue: SEK 172.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -164x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market2.73%
Healthcare6.32%
Healthtech7.28%
Pharma7.23%
Biotech6.26%
Healthcare Services6.10%
Medical Equipment6.05%
Life Sciences5.49%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 116x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 407.607.2%
+SEK 9.5b		44.0%PE294.8x
SECT B SectraSEK 237.807.5%
+SEK 3.2b		-5.6%PE85.2x
CAMX CamurusSEK 498.6010.6%
+SEK 2.9b		-13.0%PE40.5x
BONEX Bonesupport HoldingSEK 219.2022.1%
+SEK 2.7b		-30.9%PE102.9x
GETI B GetingeSEK 193.254.6%
+SEK 2.3b		-11.1%PE23.3x

Latest News

VICO
SEK 10.58
Vicore Pharma Holding
7D
-2.8%
1Y
46.9%
CRNO B
SEK 6.27
Cereno Scientific
7D
-2.1%
1Y
2.7%
BONEX
SEK 219.20
Bonesupport Holding
7D
22.1%
1Y
-30.9%
SOBI
SEK 407.60
Swedish Orphan Biovitrum
7D
7.2%
1Y
44.0%
DMYD B
SEK 1.44
Diamyd Medical
7D
-89.8%
1Y
-82.8%
CAMX
SEK 498.60
Camurus
7D
10.6%
1Y
-13.0%

CAMX: FDA Review Of Resubmitted NDA Will Drive Future Upside

Analysts have trimmed their 12 month price target for Camurus from SEK 660 to SEK 610, citing updated assumptions that include revised revenue growth, profit margin and future P/E expectations. What's in the News Camurus issued earnings guidance for 2026, with expected revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b, framed against internal 2025 expectations (Key Developments).
GETI B
SEK 193.25
Getinge
7D
4.6%
1Y
-11.1%

Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next

Mar 29
Getinge AB (publ) Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
MAGLE
SEK 4.20
Magle Chemoswed Holding
7D
-44.0%
1Y
-85.6%
ASKER
SEK 69.88
Asker Healthcare Group
7D
6.8%
1Y
-14.9%
FLUO
SEK 37.00
FluoGuide
7D
-6.3%
1Y
-2.8%
CURAS
DKK 14.15
Curasight
7D
-10.2%
1Y
77.8%
VIMIAN
SEK 28.88
Vimian Group
7D
10.5%
1Y
-34.5%
SECT B
SEK 237.80
Sectra
7D
7.5%
1Y
-5.6%

SECT B: Cloud Deals And Rating Upgrades Will Shape Balanced Return Profile

Sectra's analyst price target has been revised from SEK 220 to about SEK 228. Analysts have issued refreshed Buy ratings and higher targets in the SEK 210 to SEK 250 range that reflect updated views on growth, profitability and future P/E assumptions.
ACE
SEK 2.81
Ascelia Pharma
7D
-6.3%
1Y
0.7%

Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus

Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?
FLERIE
SEK 30.50
Flerie
7D
-14.8%
1Y
-29.8%
IMP A SDB
SEK 46.75
Implantica
7D
15.3%
1Y
62.9%